The Alliance for Regenerative Medicine (ARM) has elected Gwendolyn Binder, Ph.D., President of Science and Technology at Cabaletta Bio, to its 2027 Board of Directors, effective January 1, 2027. Binder brings more than two decades of experience in the translational development and manufacturing of engineered T cell therapies.
Binder is one of six new directors announced at ARM’s 2026 Cell & Gene Meeting on the Mesa in Phoenix. The board will guide ARM’s new multi-year strategic plan, which focuses on regulatory modernization, the commercial model and patient access, sector sustainability, and global positioning. ARM Board Chair Bob Smith said the incoming directors “bring hands-on experience building companies, bringing products to patients.” Cabaletta said her selection reflects a career spent advancing engineered T cell therapy, and thanked her for representing the company on the global stage for cell and gene therapy.
About Gwendolyn Binder
Binder joined Cabaletta Bio in February 2019 as Executive Vice President of Science and Technology, one of the company’s first employees, and built its research, manufacturing, and quality functions. She was named President of Science and Technology in January 2022 and now leads research and manufacturing strategy for the company’s cell therapies for autoimmune disease. Since 2020, she has also served as a non-executive board member at Instil Bio and on the board of advisors at Immatics.
Before Cabaletta, Binder spent nearly eight years at Adaptimmune. She joined in 2011 as a founding member of its U.S. office, then served as Executive Vice President and Head of Clinical and Regulatory Affairs, where she moved manufacturing and regulatory responsibilities from academia to in-house operations. She later led the company’s Translational Sciences group across the U.K. and U.S. From 2016 to 2019, she was Chief Technology Officer, overseeing research and translational science and building out the manufacturing team until the company’s onsite cell manufacturing facility opened in late 2017.
Earlier, as Director of Translational Research Operations at the University of Pennsylvania from 2006 to 2011, Binder designed and wrote five Investigational New Drug submissions to the FDA, covering CD19-CAR, zinc finger nuclease, and affinity-enhanced TCR technologies. She began her career at Virxsys where she contributed to the first IND evaluating a lentiviral vector in human trials.
Binder holds a B.A. in Biochemistry and Molecular Biology from Wells College and a Ph.D. in Cellular and Molecular Medicine, with a focus on viral immunology, from the Johns Hopkins University School of Medicine.
About Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine is the leading international advocacy organization for engineered cell therapies and genetic medicines and their benefits for patients, healthcare systems, and society. ARM convenes the sector, facilitates exchanges on policy and practice, and uses data and analysis to make the case for the field. It works with key stakeholders to enable the development of advanced therapies and to modernize healthcare systems so patients can benefit from durable, potentially curative treatments. ARM represents more than 400 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.
